An ALOX15 inhibitor, N-benzyl-N-hydroxy-5-benzamidine (BHPP), has been shown to reduce 12-HETE in urine and significantly improve DKD over four months of treatment. This evidence concerns the gene ALOX15 and diabetic kidney disease.